On the basis of the FGBI ARRIAH, the development of an inactivated emulsion vaccine against avian influenza (H5) has been completed and state registration has been received

Rosselkhoznadzor Order No. 1152 dated August 1, 2022 adopted a decision on the state registration of a medicinal product for veterinary use AviFluVac, a vaccine for the prevention of avian influenza developed by scientists from the Federal Center for Animal Health, which is the OIE Reference Laboratory for highly pathogenic, low pathogenic avian influenza and Newcastle disease.

The vaccine was developed for the implementation of anti-epizootic measures in Russia and foreign countries, and is intended for the prevention of influenza A subtype H5 in birds kept in poultry farms, in private farms and zoos in high-risk areas.

The advantage of the new vaccine lies in its high immunogenicity, i.e. the ability to protect birds from infection with topical highly pathogenic influenza A viruses subtype H5. The drug differs from its main competitors in high safety associated with the use in its composition of an antigen made on the basis of a low-pathogenic influenza A virus of subtype H5. The use of antigens based on low pathogenic influenza A in the composition of the vaccine is recommended by the guidelines of the World Organization for Animal Health (OIE).

Vaccination is an important tool in the fight against highly pathogenic H5 avian influenza in a difficult epizootic environment.

Source: Press service of the FGBI "ARRIAH"